LEADER 04570nam 2200673 450 001 9910483797603321 005 20230531130815.0 010 $a3-030-63369-1 024 7 $a10.1007/978-3-030-63369-1 035 $a(CKB)5590000000486821 035 $a(DE-He213)978-3-030-63369-1 035 $a(MiAaPQ)EBC6640497 035 $a(Au-PeEL)EBL6640497 035 $a(OCoLC)1255596234 035 $a(PPN)258876816 035 $a(EXLCZ)995590000000486821 100 $a20220203d2021 uy 0 101 0 $aeng 135 $aurnn#008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aColon cancer diagnosis and therapy$hVolume 1 /$fGanji Purnachandra Nagaraju, Dhananjay Shukla, Naveen Kumar Vishvakarma, editors 205 $a1st ed. 2021. 210 1$aCham, Switzerland :$cSpringer,$d[2021] 210 4$dŠ2021 215 $a1 online resource (XII, 369 p. 20 illus. in color.) 311 $a3-030-63368-3 320 $aIncludes bibliographical references and index. 327 $aEpidimology of colorectal cancer -- Colorectal cancer: A model for the study of cancer immunology -- Impact of Covid-19 Pandemic on Gastro Intestinal Cancer Patients: An Emphasis on Colorectal Cancer -- Potential role of NMR and MRI in colon cancer -- Role of micro-RNA in-situ hybridization in colon cancer diagnosis -- Role of epigenetics in colorectal cancer -- Exosomal biomarkers in colorectal cancer -- Biomarkers as putative therapeutic targets in colorectal cancer -- Proteins involved in colorectal cancer: Identification strategies and possible roles -- Short-chain fatty acids as therapeutic agents in colon malignancies -- Targeting of angiogenesis for colorectal cancer therapy -- Anti?inflammatory molecular mechanism and contribution of drug transport molecules in colorectal cancer cells -- Emerging role of circulating tumour DNA in treatment response prognosis in colon cancer -- Immuno-modulating mediators of colon cancer as immunotherapeutic: mechanism and potential -- Immune checkpoint inhibitors as armor for targeted immunotherapy of colorectal cancer -- Examining the role of the MACC1 gene in colorectal cancer metastasis -- Index. 330 $aColorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis. This book is the first of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage also addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutic, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer. 606 $aColon (Anatomy)$xCancer$xDiagnosis 606 $aColon (Anatomy)$xCancer$xTreatment 606 $aColorectal Neoplasms 606 $aColonic Neoplasms 606 $aCāncer colorectal$2thub 606 $aEpidemiologia$2thub 606 $aTractament adjuvant del cāncer$2thub 606 $aTerapia$2thub 608 $aLlibres electrōnics$2thub 615 0$aColon (Anatomy)$xCancer$xDiagnosis. 615 0$aColon (Anatomy)$xCancer$xTreatment. 615 2$aColorectal Neoplasms. 615 2$aColonic Neoplasms. 615 7$aCāncer colorectal 615 7$aEpidemiologia 615 7$aTractament adjuvant del cāncer 615 7$aTerapia 676 $a616.99 702 $aNagaraju$b Ganji Purnachandra 702 $aShukla$b Dhananjay 702 $aVishvakarma$b Naveen Kumar 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910483797603321 996 $aColon Cancer Diagnosis and Therapy$92807531 997 $aUNINA